Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 72
Special Issue Editors
2. Laboratory “Health Systemic Process” (P2S), UR4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1, University of Lyon, 7 Rue Guillaume Paradin, 69008 Lyon, France
Interests: antimicrobial agents; clinical microbiology; cell biology; biomaterials; immunology
Interests: cell biology; antimicrobial agents; photodynamic therapy
Special Issues, Collections and Topics in MDPI journals
Interests: peptides; antimicrobial agents; biochemistry
Interests: microbiology and host interaction; oral healthy and systemic diseases; periodontal diseases
Special Issue Information
Dear Colleagues,
The escalating prevalence of hospital-acquired multidrug-resistant bacterial infections (MDRIs) represents a dual crisis in modern medicine, demanding urgent innovation in antimicrobial therapies. Clinically, these infections lead to severe complications, prolonged hospitalizations, and increased mortality, particularly among immunocompromised patients, post-surgical cases, and ICU admissions. Traditional antibiotics often fail against resistant strains, leaving limited treatment options and forcing reliance on last-resort drugs with significant toxicity. Economically, MDRIs impose staggering costs due to extended ICU stays, complex infection control measures, and the need for expensive salvage therapies burdening healthcare systems already under strain. Without novel interventions, such as phage therapy, next-generation antibiotics, and precision antimicrobial strategies, the financial and human toll will intensify. Investing into advanced therapeutics is not just a scientific priority but a public health necessity, leading to reduced morbidity, curbed resistance spread, and alleviated unsustainable economic burden on global healthcare infrastructure.
We invite readers of this prestigious journal to contribute their recent discoveries regarding the fight against multidrug-resistant microorganisms.
We look forward to receiving your contributions.
Acknowledgments: We would like to thank Dr. Diego Garcia, a young scientist, who will serve as the specialist advisor for this Special Issue, for his valuable contributions. His daily clinical experience provides crucial insights into this alarming public health issue, and we greatly appreciate his participation.
Prof. Dr. Lucas de Paula Ramos
Prof. Dr. Cristina Pacheco-Soares
Dr. Hugo Vigerelli
Prof. Dr. Florence Carrouel
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial agents
- gram-negative aerobic rods and cocci
- vancomycin resistance
- cross-infection
- infection control
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
